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Abstract: In advanced chronic kidney disease, obesity may bring a survival advantage, but many
transplant centres demand weight loss before wait-listing for kidney graft. The case here described
regards a 71-year-old man, with obesity-related glomerulopathy; referral data were: weight 110 kg,
Body Mass Index (BMI) 37 kg/m2, serum creatinine (sCr) 5 mg/dL, estimated glomerular filtration
rate (eGFR) 23 mL/min, blood urea nitrogen (BUN) 75 mg/dL, proteinuria 2.3 g/day. A moderately
restricted, low-protein diet allowed reduction in BUN (45–55 mg/dL) and good metabolic and kidney
function stability, with a weight increase of 6 kg. Therefore, he asked to be enrolled in a weight-loss
program to be wait-listed (the two nearest transplant centres required a BMI below 30 or 35 kg/m2).
Since previous low-calorie diets were not successful and he was against a surgical approach, we chose
a qualitative, ad libitum coach-assisted diet, freely available in our unit. In the first phase, the diet
is dissociated; he lost 16 kg in 2 months, without need for dialysis. In the second maintenance
phase, in which foods are progressively combined, he lost 4 kg in 5 months, allowing wait-listing.
Dialysis started one year later, and was followed by weight gain of about 5 kg. He resumed the
maintenance diet, and his current body weight, 35 months after the start of the diet, is 94 kg, with a
BMI of 31.7 kg/m2, without clinical or biochemical signs of malnutrition. This case suggests that our
patients can benefit from the same options available to non-CKD (chronic kidney disease) individuals,
provided that strict multidisciplinary surveillance is assured.
Keywords: chronic kidney disease; obesity; wait-listing for kidney transplantation; dialysis; weight
loss; coach assisted diet; ad libitum diet
1. Background
The obesity pandemic is spreading worldwide [1–5]. Obesity is not only a major cardiovascular
risk factor, but also an important element in the development of a wide range of chronic kidney
diseases (CKD), including nephroangiosclerosis, and focal segmental glomerulosclerosis and diabetic
nephropathy; the relationship between diabetes and obesity is so close that it has led to the coining of
the word “diabesity” [6–13].
The pathogenesis of CKD in obese patients is complex. It can include glomerular hyperfiltration,
chronic inflammation, derangements in lipid metabolism, intraglomerular hypertension and sclerosis [6–13].
While obesity represents a progression factor for all kinds of CKD, a specific picture, called
obesity-related glomerulopathy (ORG), has recently been described. Its features include glomerulomegaly
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and the perihilar variant of focal segmental glomerulosclerosis (FSGS); from a clinical point of view,
nephrotic proteinuria is common, while full-blown nephrotic syndrome is rare. Progression to kidney
failure may occur, even in the absence of other lesions and diseases [14–18].
The importance of obesity in the pathogenesis of CKD is so high that the 2016 World Kidney Day
was dedicated to this issue [6].
Obesity has a dual meaning in advanced CKD. On one hand, when dialysis is started, clinicians
and patients are faced with what is called the obesity paradox—a survival advantage in obese patients
on dialysis [19–22]. The overall obesity paradox is due to contrasting long-term and short-term
consequences of obesity—while obesity increases long-term cardiovascular mortality, it may attenuate
short-term mortality associated with malnutrition, inflammation, and protein–energy wasting [19–22].
On the other hand, this epidemiological paradox leads to a clinical paradox with respect to
kidney transplantation. The transplantation issue is particularly complex; indeed, obesity significantly
increases the risk of mortality and graft loss, as compared to patients with normal weights. Furthermore,
the risk of surgical and post-surgical problems is increased, including retarded wound healing and
infection, lymphocele, new onset diabetes after transplant, and cardiovascular disease [23,24]. The issue
is important to the point that even if formal contraindications are seldom posed in the current
guidelines, some transplant centres systematically choose not to wait-list obese patients [25–31].
However, the impact of obesity on patient survival after kidney transplantation remains somewhat
controversial; while results of transplantation in obese patients may be less favorable than in patients
with a normal body weight, transplanted obese patients share a similar advantage to non-obese patients
with respect to dialysis. Partly as a consequence of these conflicting data, policies are not homogeneous
and “medically controlled” weight loss is often required as a pre-requisite for wait-listing [24–33].
In such a setting, many experts hold that obesity should not constitute an absolute contraindication to
transplantation, and that individualized risk assessment is necessary [23,24].
The controversy about weight loss is still open—the arguments in favour of having patients
lose weight before kidney transplantation include the clinical plausibility of the advantage of weight
loss in dialysis patients, in keeping with what is observed in the overall population, the obvious
advantage of a shorter hospital stay, and lower costs of transplantation in non-obese versus obese
patients. From an ethical point of view, having to cope with organ shortages suggests adopting a policy
of careful allocation to those who would benefit most from transplantation [34]. However, losing
weight may be difficult, if not impossible, for many patients, thus retarding or blocking their access to
a treatment which is associated with an overall survival advantage [35].
2. Several Points Need to Be Clarified
The equivalent rates of survival after transplantation in obese and non-obese patients may reflect
differences in selection criteria. Obese patients are more carefully selected from a cardiovascular point
of view, and are only accepted in some committed centres, thus introducing a potentially relevant
centre effect [34–36].
Weight loss on dialysis has been associated with lower rates of survival; however, few studies have
distinguished between intentional and non-intentional weight loss and, especially in early dialysis
follow-up, rapid weight loss may be a sign of poor pre-dialysis care and of cardiac disease, which are
both associated with lower survival rates. A further significant factor is that surgical procedures to
induce weight loss are not devoid of risk and, as a consequence, to cite the moderators’ views in
the controversy over making weight loss a requirement for transplantation—recently published in
Nephrology Dialysis and Transplantation—our approach should be to cautiously evaluate all the
factors involved (“cum grano salis”). The problem is, in every sense, a weighty one, and each patient’s
needs deserve to be taken into consideration and addressed [36].
It is in this context that we will present a short and pragmatic narrative review of the weight-loss
options for CKD patients waiting for kidney transplantation.
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We also see this as an opportunity to contextualise a case treated in the pre-dialysis phase,
using a relatively unexplored approach, based on having the patient follow a qualitative, ad libitum
coach-assisted diet (i.e., the patient had an individual counsellor who provided encouragement and
advice and ensured compliance with dietary restrictions), which had previously been tested in a small
cohort of dialysis patients [37].
3. The Case: Presentation of the Case and Problems Related to It
A 71-year-old man, affected by stage 4 CKD, was referred to our nephrology unit in June 2013 for
the prescription of a low-protein diet. He had been overweight since adolescence, and over the years
his body mass index (BMI) had ranged from 35 to 40 kg/m2. At referral to our unit, he weighed 110 kg
and had a BMI of 37 kg/m2.
The first detection of urinary abnormalities had occurred ten years before, when he underwent a
subtotal parathyroidectomy for primary hyperparathyroidism. On the same occasion he was found to
be hypertensive and anti-hypertensive treatment was started.
The clinical picture of obesity, mild hypertension concomitant with the first signs of kidney disease,
sub-nephrotic proteinuria and obesity suggested obesity-related glomerulopathy. A kidney biopsy
was not proposed at referral, as it was unlikely to change clinical management of the case. At referral
serum creatinine (sCr) was 5 mg/dL, estimated glomerular filtration rate (eGFR), calculated using the
CKD-EPI formula, was 23 mL/min, blood urea nitrogen (BUN) was 75 mg/dL, with sub-nephrotic
proteinuria (2.3 g/day). The patient was started on the moderately restricted low-protein diet we
generally prescribe (a plant-based diet with protein intake of 0.6 g/kg/day, supplemented with
alpha-ketoacids, and amino acids, with two unrestricted meals per week, as elsewhere described in
detail [38,39]).
For obese patients we usually calculate an average between ideal and real body weights to
determine the protein intake—in fact, targeting to real weight would lead to a high protein intake,
while targeting to the ideal weight is often an unreachable goal.
Compliance was good and there was an initial reduction in BUN (45–55 mg/dL), and relatively
good metabolic and kidney function stabilities. One year later, sCr was 6 mg/dL, BUN was 60 mg/dL,
calcium was 9.6 mg/dL, and phosphate was 5.1 mg/dL, while proteinuria ranged from 2 to 3 g per day,
with normal serum albumin (4.4 g/dL) and no electrolyte imbalances. However, as the diet is based
on carbohydrates, his body weight had increased by 6 kg, producing a BMI of 38.8 kg/m2.
The patient had originally opted for haemodialysis, and an Arterio venous (AV) fistula
was planned. Since he found dialysis severely intrusive in his everyday life and with his work
as a consultant, which frequently involved travelling in Italy, he asked to be waitlisted for kidney
transplantation. Since one of the two nearest transplant centres required that BMI be below 35 kg/m2,
and the other centre only waitlisted patients whose BMI was under 30 kg/m2, the patient also asked
to be enrolled in a weight-loss program.
4. Several Options Were Explored
The patient reported that he had followed a classic low-calorie diet several times, had lost weight
only for short periods, and rapidly regained it. He was against a surgical approach, in part, on account
of the lack of a local referral group with specific experience with pre-dialysis and dialysis patients.
Given our group’s favourable experience with a coach-assisted qualitative program for weight loss
(Bioimis Accademia Alimentare), we enrolled him in the study called “RENIRE” (proteggere il RENe
col dimagrIRE: protecting the kidney by losing weight; ethical committee approval: 216-2012 san
Luigi Hospital). Within the setting of this study, the patient was given free consulting sessions with a
dietician (Coaching Bioimis®).
Before starting the diet, because of the risk of rapid reduction in kidney function after
discontinuation of the low-protein diet and in the hypercatabolic phase linked to weight loss, a proximal
artero-venous fistula was prepared, and the patient started to be evaluated for kidney transplantation.
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This included a cardiology assessment, both to secure the diet phase and to control for the absence of
major contraindications for transplantation.
No sign of severe cardiac disease was found, while echocardiography demonstrated left
ventricular hypertrophy, Ejection fraction (EF) 58%, slight atrial enlargement and increased
myocardial mass.
5. The Case: The Diet
The diet is divided into two phases: rapid weight loss and slower weight-loss and maintenance.
In the first phase, the foods are selected by the nutritional coach on the basis of their glycemic index,
biochemical properties and on the effect they have on increasing or decreasing the patient’s weight
(data are recorded every day, to identify the most favourable “menus”). In this phase, the mean
carbohydrate intake is 10–15%, protein intake is 25–30%, lipid intake is 60%, and the minimum energy
intake is about 1000 kcal/day. On average, the amount of protein per kg of body weight in this phase is
1.1–1.2 g/kg/day, though the variability is high, on the account of the different meals, and the free size
of the portions (ad libitum). In fact, in this first phase, the diet is dissociated, and only one or two foods,
in unrestricted quantities are allowed at each meal.
In the maintenance phase, foods are combined together eventually making an overall
Mediterranean menu (mean intake: carbohydrates 30–50%, proteins 20% corresponding to about
0.8–1 g/kg/day, lipids 30–50%). In both phases, the diet is alcohol free and the patient is not allowed
to add sugar or, in general, salt; in severe CKD; however, salt reduction is less extreme, and is tailored
to each patient. Generous amounts of extra virgin olive oil can be used and there are no limits on
adding spices or herbs. Examples of the different menus are presented in Tables 1–3.
Table 1. Examples of menus in the rapid weight-loss phase.
Day Breakfast Lunch Dinner
Monday artichokes swordfish courgettes
Tuesday artichokes swordfish courgettes
Wednesday basmati rice spinach onions
Thursday basmati rice spinach onions
Friday broccoli turkey breast mushrooms
Saturday broccoli turkey breast mushrooms
Sunday spaghetti pork fillet asparagus
In this phase patients can eat a generous portion of each food on the menu, dressed with a liberal amount of extra
virgin olive oil but without added salt.
Table 2. Examples of menus in the weight-maintenance phase.
Day Breakfast Lunch Dinner
Monday vegetable omelette mixed salad of lettuce, shrimp, eggs,tuna fish or chicken and avocado choice of fish (no shellfish)
Tuesday strawberry mousse pasta with courgettes or aubergines andcream choice of meat, vegetables
Wednesday unsalted bread with olive oil pasta with vegetables choice of fish (no shellfish)
Thursday strawberries with cream andfructose
polenta with stewed rabbit and
mushrooms mixed beans with onions
Friday spaghetti with olive oil and chillipepper Basmati rice with shrimp mixed vegetables
Saturday yogurt with hazelnut-cocoacream and toasted nuts
Basmati rice with chopped meat, lentils
and onions choice of meat, vegetables
Sunday yogurt with oat flakes, walnutsand almonds rice with vegetables choice of fish (no shellfish)
Note: In the maintenance phase, an ad libitum approach is followed. The approximate size of portions is indicated
but patients do not need to weigh their food.
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Table 3. Examples of menus in the second weight-loss, maintenance phase: a modified LPD-KA diet
with 3 meals per week with unrestricted amounts of animal-derived proteins.
Day Breakfast Lunch Dinner
Monday unsalted bread with olive oil
mixed salad with lettuce,
carrots, eggs, avocado and
soybean sprouts
mixed beans with onions
Tuesday strawberries with soy cream whole wheat pasta withvegetables and soy cream
choice of fish (no
shellfish),vegetables
Wednesday unsalted bread with olive oil pasta with vegetables eggs, vegetables
Thursday choice of fresh fruit with mixed nuts whole wheat pasta withchickpeas
chicken or turkey.
vegetables
Friday unsweetened soy yogurt withhazelnut-cocoa cream and toasted nuts polenta with mushrooms mixed beans with onions
Saturday unsalted bread withhazelnut-cocoa cream
Basmati rice with lentils and
onions
mushrooms, aubergines
and onions
Sunday unsweetened soy yogurt with oat flakes,walnuts and almonds rice with vegetables
courgettes, broccoli and
artichokes
LPD-KA: Low protein diet supplemented with ketoacids and aminoacids. Note: In this phase, portion sizes are
specified. Patients do not need to weigh their food but should not eat more than the amount indicated in the
diet (except for the 1 to 2 protein-unrestricted meals allowed each week). Keto-analogues are taken as a dietary
supplement: 1 pill per 8–10 kg of body weight per day.
At the start of the diet, blood pressure was well controlled (115/70 mmHg); body bio-impedance,
performed with BCM Fresenius Kabi, showed moderate hyper-hydration of +2.8 L and a lean
tissue index of 17.9 kg/m2 and fat tissue index of 19.4 kg/m2; the main anthropometric measures,
the biochemical data and the changes over time for bioimpedance are reported in Tables 4 and 5.
Table 4. Anthropometric data at baseline, 2 months, 5 months, 12 months and end of follow-up.
Baseline
2 Months
“Rapid Weight
Loss”
5 Months
“Maintenance
Phase”
12 Months
“Maintenance Phase
with KA”
35 Months “End of
Follow Up” **
Weight (kg) 116 99.7∆−16.3
95.5
∆−20.5
102
∆−14
94
∆−22
BMI (kg/m2) 38.8
33.4
∆−5.4
31.9
∆−6.9
34.1
∆−4.7
31.7
∆−7.1
Bioimpedance OH
(kg/m2) 2.8 1.5 1.1 5.5 −3.1
Bioimpedance FTI
(kg/m2) 19.4
12.7
∆−6.7
11.6
∆−7.8
14.8
∆−4.6
17.9
∆−1.5
Bioimpedance LTI
(kg/m2) 17.9
19.8
∆1.2
19.5
∆1.6
16.9
∆−1
14.1
∆−3.8
Handgrip (kg) 33.8 25.8 28.0 32.6 Na
Waist circumference
(cm) 127
111
∆−16
116
∆−11
115
∆−12
112
∆−15
Bioimpedance measurement (performed with BCM Fresenius): BMI: Body Mass Index; OH: overhydratation
(litre) represents the excess fluid stored almost exclusively in the extracellular volume; LTI: Lean Tissue Index
(weight/height2) quotient of lean tissue mass/height2; FTI: Fat Tissue Index (weight/height2) quotient of adipose
tissue mass/height2; ** Data at end of follow up refers to pre dialysis session.
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Table 5. Biochemical data at baseline, 2 months, 5 months, 12 months and end of follow-up.
Baseline
2 Months
“Rapid Weight
Loss”
5 Months
“Maintenance
Phase”
12 Months
“Maintenance Phase
with KA”
35 Months “End of
Follow Up” *
sCr (mg/dL) 6.2 7.8 8.6 7 8.5
eGFR CKD-EPI 8 6 6 7 NA (dialysis)
BCrC (mL/min) 16 15 11 11 NA (dialysis)
BUN (mg/dL) 60 94.8 98.6 93.9 74.8
Proteinuria (g/day) 2.1 4.2 2.6 3.6 NA (dialysis)
Sodiuria (mmol/day) 228 231 117,5 170,5 NA (dialysis)
Hb (g/dL) 11 11.8 11.1 10.7 10.0
Calcium (mg/dL) 8.9 8.3 9.3 9 10.2
Phosphate (mg/dL) 4.4 5.2 5 5.9 4
iPTH (pg/mL) 314 761 358 330 93
HCO3 (mmol/L) 25.6 32.3 22.3 24 21.5
Serum Albumin (mg/dL) 4.4 4.3 4.4 3.8 3.5
sCr: serum creatinine; BCrC: creatinine clearance on 24-h urine collection; eGFR: estimated glomerular filtration
rate calculated using CKD-EPI formula; BUN: blood urea nitrogen; Proteinuria: proteinuria excretion on 24-h urine
collection; Hb: serum haemoglobin; iPTH: intact parathyroid hormone; HCO3: serum bicarbonate. * Data at end of
follow-up refers to start of dialysis.
After discontinuation of the low-protein diet and the start of the weight-reduction program,
there was a sharp decrease in the patient’s residual renal function, probably linked to the restricted
sodium intake (80–100 mEq/day) and relative dehydration (as also witnessed by the presence
of alkalosis). Dialysis was not needed, due to his overall well-being, good blood pressure control,
preserved albumin and haemoglobin levels, and electrolyte balance, in spite of the increase in
proteinuria, probably linked to the discontinuation of protein restriction (Table 5). The patient lost
16 kg in this phase (Table 4).
In the first maintenance phase, a further 4 kg were lost in 5 months, followed by moderate
weight gain, and then stabilization at 14 kg less than his pre-diet weight. This made it possible for him
to be waitlisted for kidney transplantation in the first centre before starting dialysis.
A maintenance vegetable-based menu was then tailored to the patient so that dialysis could
be delayed as long as possible. Dialysis was started one year later, when kidney function further
deteriorated, with the development of resistant hyperphosphatemia, although in the absence of uremic
symptoms and acidosis—at the first dialysis session, sCr was 11.5 mg/dL, BUN was 107 mg/dL,
phosphate was 7 mg/dL, potassium was 5.5 mmol/L, serum albumin was 4.1 g/dL and haemoglobin
was 10.4 g/dL.
After the first dialysis phase, in which he regained about 5 kg in 4–6 months, he started the
maintenance diet again, to reach the weight required by the second transplant centre (BMI below
30 kg/m2). His current body weight, 35 months after the start of the diet, is 94 kg, with a BMI of
31.7 kg/m2; his recent bioimpedance data showed hydration of−3.1 L, lean-tissue index of 14.1 kg/m2
and fat-tissue index of 17.9 kg/m2. In the last phases of follow-up, adipose tissue mass increased
slightly, while lean tissue mass decreased. This was probably due to several factors, including the
age-related muscle atrophy (the patient being at that time, 74 years old), decrease in physical activity
after the start of dialysis and the treatment’s catabolic effects, in spite of good dialysis efficiency
(Kt/V 1.3–1.4, according to Daugirdas 2).
6. Discussion
6.1. The Paradox of Losing Weight in the Pre-Dialysis Phase
The paradox of longer survival of obese patients in dialysis—the paradigm of reverse
epidemiology—underlines the importance of maintaining good nutritional status while on dialysis;
hence, many authors hold that weight loss on dialysis is dangerous, failing to consider the fact that
most of the large studies that have been done do not distinguish between intentional and unintentional
weight loss in dialysis patients [4,5,19–22,40].
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The unclear dangers of weight loss have to be balanced against the very real advantages of
being eligible for kidney transplantation, a treatment that has a well-recognised survival advantage,
also shared by overweight and obese patients [25–30,34–36]. While this balance would shift if policies
on transplantation for obese patients were more liberal, at present losing weight is often the only way
for an obese patient to get waitlisted for this treatment [34–36].
Conversely, losing weight in the pre-dialysis phase is sometimes reported to slow the progress
of kidney disease. This is difficult to evaluate, however, as most trials and series concern relatively
early CKD stages, in which the advantage of weight loss may counterbalance the negative effects
dieting has on nutritional status [41–43]. Even less is known about the last phases of CKD. In these
phases, losing weight allows patients to be waitlisted for kidney transplantation, but weight-loss
induced hyper-catabolism and dialysis contribute to impairments in nutritional status [43,44].
Being hyper-catabolic can have a negative effect on a patient’s reduced kidney function, and there
is a significant risk that this will lead to hyperkalaemia, hypophosphatemia and acidosis [45,46].
Furthermore, which dietary approach is most successful in allowing pre-dialysis and dialysis patients
to lose weight has not yet been established. The recent consensus statement from the Asian Pacific
Society of Nephrology (APSN) underlines the extent to which we lack evidence showing how the
dietetic management of overweight and obese individuals with CKD should be approached. While the
conclusions reached are rather disheartening, and no real consensus is reached on most of the items
discussed, the fact that the APSN statement notes that medical or surgical strategies to facilitate weight
loss “require a multidisciplinary approach with the involvement of a skilled renal dietician” indirectly
demonstrates the importance of a tailored approach to each CKD patient [41].
Our patient’s story highlights the difficulties inherent in this phase, in particular, the need for
careful control in the phase of rapid weight loss, so that acidosis, hyperkalemia and a rapid decrease in
renal function can be avoided.
6.2. Low-Protein Diets and Weight Loss
In our patient, it was almost impossible to disentangle the effects on kidney function and
proteinuria caused by discontinuation of his vegetable-based, supplemented low-protein diet and those
due to weight loss. Our hypothesis is that the increase in proteinuria was related to the discontinuation
of his supplemented vegetable-based diet, which we believe led to a reduction in proteinuria [47–49].
Conversely, we thought that the rapid decrease in kidney function was mainly due to sodium restriction
and relative hypotension (Table 5). In keeping with this interpretation, kidney function later stabilised
and the patient was able to remain dialysis-free for over a year.
A protein-restricted diet is usually considered to be incompatible with a calorie-restricted or
weight-loss diet. Yet interestingly, when combining several Medical Subject Headings (MESH) and free
terms on obesity, protein restriction, weight loss and CKD we found no relevant reports on Medline.
This issue was not even commented on in APSN’s best practice statement, while the association of
the two nutritional approaches was contraindicated in a recent statement by the Italian Society of
Nephrology [41,50].
Our case suggests that, in selected patients, the two approaches can be combined without
producing short-term detrimental effects. However, we cannot exclude that the moderate reduction in
lean-body mass observed in our patient at the end of follow-up, that we considered as probably due to
the hypercatabolic effect of dialysis, was at least partly due to the vegetable-based, supplemented diet
he had followed in the weight-control maintenance phase, before starting dialysis (Tables 2 and 4).
6.3. Calorie-Restricted Diets in Advanced CKD
Controlling weight is difficult for all obese patients, whether or not they have CKD, and the
results are often disappointing [41,50]. The classic approach of reducing calories conflicts with two of
the usual indications for CKD patients: a high calorie intake to minimise the hypercatabolism linked
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to uraemia, acidosis, and chronic disease; and the negative effect of weight loss in patients starting
renal replacement therapy [42].
However, the “magic numbers” of 30–35 kcal/kg day, that are usually indicated for
uremic patients, are derived from a small number cases, studied over four decades ago, in a completely
different population (younger, with a lower prevalence of diabetes and obesity). While the overall
indications are a matter of discussion, there is widespread agreement that they do not apply to obese
patients [43,49–51]. Furthermore, no indication of the “ideal” calorie intake in this population is
available, and, consequently we lack a precise idea of what the calorie restrictions imposed should be.
While calorie restriction of whatever entity is often beneficial for CKD patients, the fact
that they are doing little physical activity and the need to conciliate a lowered calorie intake
with other restrictions—which in advanced CKD and dialysis include limiting potassium and
phosphate—obviously makes designing an adequate diet more complicated. Our patient had gone
on traditional calorie-restricted diets several times but had never managed to maintain weight loss,
a situation that is quite common in obese patients. Hence, he was reluctant to start a new diet based on
the same principles. We agreed, as we felt that this approach, albeit potentially effective in patients who
have never attempted to lose weight in this way, was unlikely to be of help in his case (previous failure,
reduced physical activity, limited applicability of high-protein diets, due to CKD, hyperphosphatemia
and acidosis, potential limitations on plant-based regimens due to the risk of hyperkalaemia).
6.4. Bariatric Surgery in Advanced CKD
Interest in bariatric surgery in CKD patients is also an indirect marker of the frequent failure of
other means for them to attain stable weight loss [52–57].
The data on bariatric surgery are contrasting: weight loss is often attained, with positive results
for kidney function, including reductions in hyperfiltration and proteinuria, and better blood pressure
control, in virtually all CKD stages, including dialysis [56]. Studies on the effect of bariatric surgery
in the strict pre-dialysis phase are lacking, but it is conceivable that the post-surgery reduction in
hyperfiltration, together with the metabolic charge linked to the rapid catabolic phase, may catalyse
the need for dialysis start.
Weight loss is not without a price. While in carefully selected patients, mortality is low,
and post-surgical morbidity does not appear to be higher than in the obese population without CKD,
and access to kidney transplantation is becoming a specific indication, long-term effects may
be important. Kidney stones, and, rarely, oxalate nephropathy, have been described in grafted
kidneys [53,57].
Pancreatitis, malnutrition and malabsorption of some drugs are further concerns in selected cases.
Side effects are more common in patients who have undergone an “omega” or classic bypass, and may
be of lesser relevance in patients who have undergone a sleeve gastrectomy, which has been proposed
by some groups, specifically to ease access to kidney transplantation [53,58–61].
Independently from the technique, and acknowledging the good results that can be obtained,
one of the main clues to whether it will be successful is the availability of an experienced referral group
with multidisciplinary experience with CKD patients. This is not yet always an option, thus limiting
de facto access to these treatments.
6.5. Coach-Assisted and ad Libitum Diets
As clinicians working with obese CKD patients became aware of the shortcomings involved
in classic calorie-restricted diets, different approaches were developed, including qualitative,
ad libitum diets, in which unrestricted quantities of specific aliments are allowed, often in a dissociated
way (i.e., one aliment at a time), and coach-assisted diets, in which compliance is reinforced by a close
relationship with one individual (the coach) who acts as a counsellor and checks that the diet is being
followed [62–70].
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While these approaches have gained attention, in particular in consolidating long-term results,
nephrologists’ experiences with obese CKD patients are extremely limited, possibly on account of
the tendency to be more conservative when treating obese patients affected by challenging clinical
problems, such as CKD. The patient discussed here was successfully treated using a coach-assisted,
ad libitum, quantitative diet, following a previous positive experience with a small group of dialysis
patients, in which this non-conventional approach was used mainly so that they could be waitlisted for
kidney transplantation [37,71]. While these few cases do not allow us to draw conclusions about such
diets’ long-term efficacies (an issue that is being addressed by a large on-going study), these “extreme”
cases serve to reassure us that these approaches are without severe intrinsic side effects, and more
generally suggest that no approach used with obese non-CKD patients should be banned a priori in
treating obese patients with CKD.
7. Conclusions
This case report reflected on the different approaches used to promote weight loss in patients with
advanced CKD. While the controversy over the advantages of weight loss and making it a requirement
for being waitlisted for kidney transplantation is still open, this case suggests that treatment should not
be limited to traditional approaches, and that our patients can benefit from the same options available
to non-CKD individuals, provided that strict multidisciplinary surveillance is available.
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